← FDA DRUG APPROVALS

FDA ANDA · ANDA079242

SUMATRIPTAN SUCCINATE

Sponsor: FRESENIUS KABI USA

APPLICATION
ANDA079242
TYPE
ANDA
ORIGINAL APPROVAL
2009-03-02
LATEST ACTION
2015-06-02
ROUTE
SUBCUTANEOUS
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

SUMATRIPTAN SUCCINATEPrescription
SUMATRIPTAN SUCCINATE EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) · INJECTABLE · SUBCUTANEOUS

Approval history

2015-06-02Labeling · Supplement 2AP
2015-06-02Labeling · Supplement 3 · standardAP
2009-03-02Original — Label ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →